Brief: FDA Investigates Death Linked to Adzynma Treatment for Congenital Thrombotic Thrombocytopenic Purpura
21/11/2025 16:42
Nov 21 (Reuters) - FDA: FDA INVESTIGATING DEATH DUE TO NEUTRALIZING ANTIBODIES TO ADAMTS13 FOLLOWING ADZYNMA TREATMENT OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom (updated)